Literature DB >> 16675561

Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma.

Marije Booman1, Jenny Douwes, Annuska M Glas, Sietske A Riemersma, Ekaterina S Jordanova, Klaas Kok, Andreas Rosenwald, Daphne de Jong, Ed Schuuring, Philip M Kluin.   

Abstract

PURPOSE AND EXPERIMENTAL
DESIGN: Loss of human leukocyte antigen (HLA) expression on tumor cells is frequent in diffuse large B-cell lymphoma (DLBCL) arising in immune-privileged sites, such as the testis and central nervous system, and is associated with small homozygous deletions of HLA-DQ/HLA-DR and larger hemizygous deletions of the MHC region. To better understand the significance of down-regulation of HLA class II expression in relation to the homozygous and hemizygous deletions, we analyzed global gene expression patterns in a series of 26 testicular DLBCL after characterization of these deletions.
RESULTS: Low levels of HLA-DR mRNA in whole testicular DLBCL samples were associated with a strong down-regulation of numerous immune-related genes specific for T cells, macrophages, antigen presentation and processing, lymphocyte activation, chemokines and chemokine receptors, and the complement system. The number of CD3+ tumor-infiltrating T cells was also significantly lower in low expressors of HLA-DR mRNA. Interestingly, hemizygous and homozygous deletions in the MHC region did not have any additional effect on global gene expression.
CONCLUSION: In conclusion, we found that loss of HLA class II mRNA expression in testicular DLBCL is associated with a significant change in global gene expression patterns. This effect is independent of the mechanism causing the down-regulation of HLA class II genes in the lymphoma cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675561     DOI: 10.1158/1078-0432.CCR-05-2617

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

Authors:  I Vater; M Montesinos-Rongen; M Schlesner; A Haake; F Purschke; R Sprute; N Mettenmeyer; I Nazzal; I Nagel; J Gutwein; J Richter; I Buchhalter; R B Russell; O D Wiestler; R Eils; M Deckert; R Siebert
Journal:  Leukemia       Date:  2014-09-05       Impact factor: 11.528

Review 2.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.

Authors:  Aurélie Bruno; Karim Labreche; Maïlys Daniau; Blandine Boisselier; Guillaume Gauchotte; Louis Royer-Perron; Amithys Rahimian; Frédéric Lemoine; Pierre de la Grange; Justine Guégan; Franck Bielle; Marc Polivka; Clovis Adam; David Meyronet; Dominique Figarella-Branger; Chiara Villa; Fabrice Chrétien; Sandrine Eimer; Frédéric Davi; Audrey Rousseau; Caroline Houillier; Carole Soussain; Karima Mokhtari; Khê Hoang-Xuan; Agusti Alentorn
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

4.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Blood Adv       Date:  2020-11-24

Review 5.  Epidemiology and biology of relapse after stem cell transplantation.

Authors:  Mary Horowitz; Hans Schreiber; Alex Elder; Olaf Heidenreich; Josef Vormoor; Christina Toffalori; Luca Vago; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2018-04-18       Impact factor: 5.483

Review 6.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

Review 7.  Fundamentals of immunology for understanding immunotherapy for lymphoma.

Authors:  Stephen M Ansell
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  Commentary on the WHO classification of tumors of lymphoid tissues (2008): aggressive B-cell lymphomas.

Authors:  Olga Balague Ponz; German Ott; Robert P Hasserjian; Kojo S J Elenitoba-Johnson; Laurence de Leval; Daphne de Jong
Journal:  J Hematop       Date:  2009-06-16       Impact factor: 0.196

9.  Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.

Authors:  L Deng; Z Y Xu-Monette; S Loghavi; G C Manyam; Y Xia; C Visco; J Huh; L Zhang; Q Zhai; Y Wang; L Qiu; K Dybkær; A Chiu; A M Perry; S Zhang; A Tzankov; H Rao; J Abramson; A R Sohani; M Xu; E D Hsi; J Zhu; M Ponzoni; S Wang; Ling Li; M Zhang; A J M Ferreri; B M Parsons; Y Li; M A Piris; L J Medeiros; K H Young
Journal:  Leukemia       Date:  2013-08-26       Impact factor: 11.528

Review 10.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.